TGen to Conduct Phase I Study of Prolexys Anti-Cancer Drug | GenomeWeb

TGen to Conduct Phase I Study of Prolexys Anti-Cancer Drug

Aug 30, 2007

Prolexys Pharmaceuticals yesterday announced the start of its first human trials of PRLX 93936, a potential anti-cancer compound.

Among the study centers performing the phase I studies of this erastin analog is TGen Clinical Research. At TGen and the other study sites, the safety, efficacy, and pharmocodynamic properties of PRLX 93936 will be evaluated in patients with advanced solid tumors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Spiders and Scorpions, Oh My!

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

Keep It Secret

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Page Joins Chronic Disease Startup

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

This Week in Cell

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.